2016_Head & Neck COURSE BOOK

Suggested literature

• Overgaard, J. et al. Five compared with six fractions per week of conventional radiotherapy of squamous‐cell  carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial The Lancet 362: 933‐940 2003 .  ,  . • Bourhis J et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta‐analysis. Lancet  2006; 368: 843–54. • Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A  systematic review and meta analysis Radiother Oncol (2011) ‐ .  • Nordsmark et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation  therapy. An international multi‐center study. Radiotherapy and Oncology 77 (2005) 18–24 • Bernier J, Licitra L. Chemoradiation in head‐and‐neck cancer—are we any closer? Nature reviews | clinical  oncology volume 7 May 2010  ,  • Pignon JP et al. Chemotherapy added to locoregional treatment for head and neck squamous‐cell carcinoma:  three meta‐analyses of updated individual data. Lancet 2000;355:949‐55.  • Pignon JP et al. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): An update on 93 randomised  t i l d 17 346 ti t R di th d O l 92 (2009) 4 14 r a s an ,  pa en s. a o erapy an nco ogy    – • Budach W. et al. A meta‐analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy  and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC  Cancer 2006, 6:28 B i J l P i I di i i h i h C i Ch h f L ll Ad d H d • ern er  et. a . ostoperat ve rra at on w t or w t out oncom tant emot erapy or oca y vance ea  and Neck Cancer. N Engl J Med 350;19, 2004 • Cooper JS et al. Postoperative concurrent radiotherapy and chemotherapy for high‐risk squamous‐cell carcinoma  of the head and neck. N Engl J Med 2004;350:1937‐44. • Bonner  JA et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival  data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncol  2010; 11: 21–28